LncRNA XIST在急性髓系白血病中的表达及其临床意义  

Expression and clinical significance of long non-coding RNA XIST in acute myeloid leukemia

作　　者：刘军[1] 郑慧敏 丁洋洋 李曼曼 胡林辉 蒲莲芳 陶千山[1] 熊术道[1] Liu Jun;Zheng Huimin;Ding Yangyang(Dept of Hematology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601;Dept of Emergency,The First Affiliated Hospital of University of Science and Technology of China,Anhui Provincial Hospital,Hefei 230001)

机构地区：[1]安徽医科大学第二附属医院血液科,合肥230601 [2]中国科学技术大学附属第一医院(安徽省立医院)急诊科,合肥230001 [3]上海交通大学附属仁济南院血液科,上海200240 [4]景德镇第三人民医院血液科,景德镇333000 [5]蚌埠第三人民医院血液科,蚌埠233000

出　　处：《安徽医科大学学报》2019年第9期1439-1443,共5页Acta Universitatis Medicinalis Anhui

基　　金：国家自然科学基金(编号:81401293);安徽省高校自然科学研究重点项目(编号:KJ2018A0198);安徽省转化医学研究院科研基金项目(编号:2017zhyx13)

摘　　要：目的探讨在急性髓系白血病(AML)患者中长链非编码RNA X染色体失活特异性转录因子(LncRNA XIST)的表达情况及其临床意义。方法收集105例AML初治组(AML)、20例AML化疗后完全缓解组(AML-CR)和20例缺铁性贫血(IDA)对照组(CON)的骨髓标本,实时荧光定量PCR(qRT-PCR)检测LncRNA XIST的表达量,分析3组之间的表达差异,探讨其表达水平与患者的临床特征及预后的相关性。结果与对照组比较, LncRNA XIST在初治AML组中低表达( P <0.001)。与初治的AML组比较,其在AML-CR组中表达明显上调( P <0.001),而AML-CR 组与对照组中LncRNA XIST表达水平的差异无统计学意义( P >0.05)。AML初治组中,LncRNA XIST的表达水平与AML分型急性髓细胞白血病部分成熟型-急性早幼粒细胞白血病/急性粒单核细胞白血病-急性单核细胞白血病(M2-M3/M4-M5)、有无髓外浸润、白细胞数及乳酸脱氢酶水平存在相关性。LncRNA XIST低表达组患者的生存率明显低于高表达组患者( P =0.018)。通过COX回归分析显示,LncRNA XIST和白球比可以作为AML独立预后因素。结论 LncRNA XIST在初治AML患者中低表达,化疗完全缓解中表达上调,且与预后相关,提示其有作为AML患者的预后标志物及治疗靶点的可能。Objective To investigate the expression and clinical significance of long non-coding RNA X chromosome inactive specific transcript(LncRNA XIST) in patients with acute myeloid leukemia(AML). Methods Bone marrow samples from 105 cases of AML initial treatment group(AML), 20 cases of complete remission group after AML chemotherapy(AML-CR) and 20 cases of iron deficiency anemia(IDA) control group(CON) were collected. real-time quantitative PCR(qRT-PCR) was used to detect the expression level of LncRNA XIST. Statistical analysis was per-formed to analyze the difference in expression level of LncRNA XIST between the three groups and to explore the correlation between the expression level of LncRNA XIST with the clinical features and prognosis of patients. Results LncRNA XIST was down-regulated in the AML initial treatment group compared with the control group( P <0.001). Compared with the AML initial treatment group, it was significantly up-regulated in the complete remission group after AML chemotherapy(AML-CR)( P <0.001). There was no statistical significance in the expression level difference of LncRNA XIST between the complete remission group after AML chemotherapy(AML-CR) and the control group( P >0.05). In the AML initial treatment group, the expression level of LncRNA XIST was correlated with AML typing(M2-M3/M4-M5), presence or absence of extramedullary infiltration, white blood cell count and lactate dehydrogenase level. The survival rate of patients with low expression group of LncRNA XIST was significantly lower than that of patients with high expression group( P =0.018).COX regression analysis showed that LncRNA XIST and ratio of albumin to globulin could be used as independent prognostic factors in AML. Conclusion LncRNA XIST is down-regulated expression in initially treated AML patients, and up-regulated in chemotherapy to complete remission, and is associated with prognosis, suggesting that it may be a prognostic marker and therapeutic target for AML patients.

关 键 词：长链非编码RNA LncRNA XIST 急性髓系白血病 预后 

分 类 号：R733.71[医药卫生—肿瘤]